Evidence map›Paper›PMID 40071089›Full record

SynthesisFrontiers in oncology2025

Evolving paradigms in prostate cancer screening: a decade of bibliometric insights and technological advancements.

Keqiang Chai, Changhong Xu, Jiangwei Man, Yun Deng, Li Yang

Abstract readSystematic Review
In one paragraph

Synthesis in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Keqiang Chai *Department of Urology, The Third Affiliated Hospital of Gansu University of Chinese Medicine, Baiyin, Gansu, China.
Changhong Xu *Department of Urology, Institute of Urology, Gansu Province Clinical Research Center for Urinary System Disease, Lanzhou University Second Hospital, Lanzhou, Gansu, China.
Jiangwei Man *Department of Urology, Institute of Urology, Gansu Province Clinical Research Center for Urinary System Disease, Lanzhou University Second Hospital, Lanzhou, Gansu, China.
Yun DengDepartment of Urology, Institute of Urology, Gansu Province Clinical Research Center for Urinary System Disease, Lanzhou University Second Hospital, Lanzhou, Gansu, China.
Li YangDepartment of Urology, Institute of Urology, Gansu Province Clinical Research Center for Urinary System Disease, Lanzhou University Second Hospital, Lanzhou, Gansu, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: Prostate cancer is a major threat to global male health. This study uses bibliometric methods to analyze the dynamics and trends in prostate cancer screening research, with the aim of optimizing screening strategies and informing policy decisions. Methods: Utilizing the Web of Science Core Collection database, this study retrieved prostate cancer screening-related literature published between 2014 and 2024, totaling 5,409 articles. Data processing and analysis were conducted using CiteSpace and the Bibliometrix R package, including citation network analysis, co-word analysis, cluster analysis, and trend analysis. Results: The analysis revealed the following key findings: (1) Global literature on prostate cancer screening has grown annually, with the United States, Europe, and China leading research activity; (2) Research hotspots include the risks and benefits of prostate-specific antigen (PSA) testing, MRI-based screening technologies, and the use of molecular and genetic biomarkers; (3) Emerging technologies, such as machine learning and nanodiagnostic techniques, are enhancing diagnostic precision and reducing overdiagnosis; (4) Network analysis of collaborations reveals a shift toward transnational and interdisciplinary research, particularly in integrating biomedical and computer science to drive rapid advancements in screening technologies. Conclusion: This study confirms the ongoing vibrancy and technological advancement in the global field of prostate cancer screening research, emphasizing the trend towards precision medicine. Future development of prostate cancer screening strategies should focus on risk-adapted screening and the application of novel biomarkers to optimize screening outcomes and reduce unnecessary medical interventions.

Indexed as

bibliometric analysisdiagnostic technologiesprecision medicineprostate cancer screeningrisk stratification

Identifiers

PMID40071089
PMCPMC11893402

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.